ROCKVILLE, Md., Aug. 13, 2014 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing
novel anti-infective biologic and drug candidates targeting
specific pathogens that cause serious infections and diseases,
announced today that it will host an Investor Day in New York to discuss the Company's irritable
bowel syndrome (IBS) program, including its novel, oral product
SYN-010, targeting constipation-predominant IBS (C-IBS).
Synthetic Biologics' CEO, Jeffery
Riley, and Joseph Sliman,
M.D., M.P.H., Senior Vice President, Clinical & Regulatory
Affairs, will provide an overview of the anticipated clinical and
regulatory pathway for SYN-010 to reduce the impact of methane
producing organisms on C-IBS, including plans to file an
Investigational New Drug (IND) application and initiate a Phase II
dose-discovery and proof-of-mechanism clinical study in the second
half of 2014. Keynote speaker, Dr. Mark
Pimentel will discuss his groundbreaking work that led to
the discovery of SYN-010, including the association between the
overproduction of methane gas by microorganisms in the gut and
conditions such as C-IBS, as well as further detail for SYN-010
itself.
Event Detail:
Tuesday, September 16, 2014
9:00 a.m. to 11:00 a.m. EDT
Grand Hyatt New York Hotel, New York
City
This event will be accessible via live webcast, to be made
available on Synthetic Biologics' website.
Keynote Speaker Bio:
Dr. Mark Pimentel is Director, GI
Motility Program and Laboratory, and Professor of Medicine at
Cedars-Sinai Medical Center in Los
Angeles, California. Active in research, Dr. Pimentel
has served as a principal investigator or co-investigator for
numerous basic science, translational and clinical studies in IBS,
and the relationship between gut flora composition and human
disease. Dr. Pimentel is the lead investigator for Synthetic
Biologics' C-IBS program, as well as the Chairman of the Company's
C-IBS Clinical Advisory Board.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology
company focused on the development of novel anti-infective biologic
and drug candidates targeting specific pathogens that cause serious
infections and diseases. The Company is developing an oral biologic
to protect the gastrointestinal microflora from the effects of IV
antibiotics for the prevention of Clostridium difficile (C.
difficile) infection, an oral treatment to reduce the impact of
methane producing organisms on constipation-predominant irritable
bowel syndrome (C-IBS), a series of monoclonal antibodies for the
treatment of Pertussis and Acinetobacter infections, and a
biologic targeted at the prevention and treatment of a root cause
of a subset of IBS. In addition, the Company is developing an oral
estriol drug for the treatment of relapsing-remitting multiple
sclerosis (MS) and cognitive dysfunction in MS. For more
information, please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
This release includes forward-looking statements on Synthetic
Biologics' current expectations and projections about future
events. In some cases forward-looking statements can be identified
by terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions. These statements are based
upon current beliefs, expectations and assumptions and are subject
to a number of risks and uncertainties, many of which are difficult
to predict and include statements regarding Synthetic Biologics'
plans to file an Investigational New Drug (IND) application
and initiate a Phase II dose-discovery and proof-of-mechanism
clinical study in the second half of 2014. The
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from those set
forth or implied by any forward-looking statements. Important
factors that could cause actual results to differ materially from
those reflected in Synthetic Biologics' forward-looking statements
include, among others, the IND filing and clinical trial not
being commenced when planned and other factors described in
Synthetic Biologics' report on Form 10-K for the year ended
December 31, 2013 and any other
filings with the SEC. The information in this release is provided
only as of the date of this release, and Synthetic Biologics
undertakes no obligation to update any forward-looking statements
contained in this release on account of new information, future
events, or otherwise, except as required by law.
Logo -
http://photos.prnewswire.com/prnh/20130522/MM19465LOGO
SOURCE Synthetic Biologics, Inc.